News
To position istaroxime for Phase 3 readiness, WINT launched the small Phase 2 study in SCAI Stage C. SCAI Stage C cardiogenic shock is a more severely ill patient population than the participants ...
Hosted on MSN1mon
Windtree reports positive Phase 2b study on heart failure therapyThe SEISMiC study focused on the effects of istaroxime in patients experiencing early (SCAI Stage ... cardiogenic shock. The company's broader portfolio includes other product candidates in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback